MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. We show 9 historical shares outstanding datapoints in our INKT shares outstanding history coverage, used to compute INKT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing INKT market cap history over the course of time is important for investors
interested in comparing INKT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of INKT versus a peer is one thing; comparing
INKT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like INKT can fluctuate over the course of history.
With this page we aim to empower investors researching INKT by allowing them to research the INKT market cap history. |
Free INKT Email Alerts:
Video: The Importance of Market Cap
